Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 151.78% ano a ano.
Avaliação Justa
O PE mais recente da empresa é 1.91, em uma faixa percentil média de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 17.75M ações, um aumento de 4.23% em relação ao trimestre anterior.
Mantido por ETHSX
O Super Investidor ETHSX possui 37.99K ações desta empresa.